Prescribing practice of long-acting injectable antipsychotics

Prescribing practice of long-acting injectable antipsychotics

Blog Article

Introduction: Nonadherence to treatment is one of the main problems that prevent treatment outcomes in schizophrenia.Long-acting injectable antipsychotic (LAIA) simplifies the treatment process and improves the adherence and health-related outcomes.The prescription pattern of antipsychotics in psychiatric and nonpsychiatric wards is well studied.

Whereas the patterns of long-acting injectable (LAI) are not yet documented.Hence, this study was aimed to assess the pattern and prescription of LAI in a university hospital in Saudi Arabia.Materials and Methods: This single-centered, retrospective study was conducted in a university teaching hospital in Khobar city over a period of 6 months.

Patients of all ages and either gender with a psychiatric safety razor diagnosis or received at least a single depot injection over a period of 1 year were included in the study.Results: A total of 101 patients were included in the study; a male predominance was observed in (64%) our study patients.One half of the study patients have a long history (10 years and more) of psychiatric problems.

Of the total 313 medications, 176 (55.7%) and 137 (43.3%) were psychotropic and nonpsychotropic medications, respectively.

Zuclopenthixol (n = 48) and haloperidol (n = 10) were the commonly prescribed first-generation LAIAs, whereas risperidone (40) was the only one second-generation LAIA preferred in the study site.Befere the Initiation of LAIA ,majority (67%)of the patients received a trial of antipsychotices orally.Conclusion: The study delivers the evidence of LAIA utilization in a psychiatric unit of a tertiary care teaching hospital in Saudi COMPLETE COLLAGEN CITRUS TWIST Arabia.

LAIAs were the choice not solitary for schizophrenic-like ailments.The utilization pattern is similar to both-generation LAIs.More studies are required to focus the safety and efficacy concerns of LAIA.